NM 505

Drug Profile

NM 505

Alternative Names: NM-505; Reformulated metformin - MicroBiome Therapeutics

Latest Information Update: 13 Jun 2015

Price : $50

At a glance

  • Originator MicroBiome Therapeutics
  • Class Antihyperglycaemics; Biguanides; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; Metagenome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Clinical Phase Unknown Type 2 diabetes mellitus

Most Recent Events

  • 09 Jun 2015 Efficacy and adverse events data from a clinical trial in Type-2 diabetes mellitus presented at the 75th Annual Scientific Sessions of the American Diabetes Association (ADA-2015)
  • 09 Jun 2015 MicroBiome Therapeutics has patent protection for microbiome modulator-metformin combination NM 505 in USA
  • 12 May 2015 MicroBiome Therapeutics receives positive response from the US FDA to use the 505(b) regulatory pathway for the development of NM 505 for the treatment of Type- diabetes mellitus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top